FOLFIRI ± Bevacizumab

Phase 2Monoclonal antibody

Pfizer

FOLFIRI ± Bevacizumab is one of 113 small molecule programs targeting Colorectal Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

112

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CarcinomaActive, not recruiting

Neuroendocrine CarcinomaActive, not recruiting

Colorectal CancerActive, not recruiting

Colorectal CarcinomaPhase 2

Active, not recruiting

Neuroendocrine CarcinomaPhase 2

Active, not recruiting

Colorectal CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

949 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Eylea

Regeneron

Preclinical

5 2

FOLFIRI ± Bevacizumab

Pfizer

Phase 2

1 3

Emend IV

Merck & Co.

Preclinical

—4

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 5

Vascepa

AAmarin Pharma Inc.

Preclinical

1 6

Bridion

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Andriol

AAuxilium

Preclinical

1 8

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 9

Gas-X

PPortuguese Oncology Institute, Coimbra

Preclinical

1 10

Ketalar

AAultman Health Foundation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Colorectal Cancer

NCT06603376

Clinical

Trials by Indication[1]

Neuroendocrine Carcinoma1 trial

Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer

Completed·HHospices Civils de Lyon·Phase 2·NCT02820857·153 enrolled

Colorectal Carcinoma1 trial

Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC)

Completed·SSpanish Cooperative Group for the Treatment of Digestive Tumours (TTD)·Phase 2·NCT01640444·240 enrolled

Colorectal Cancer1 trial

Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer

Recruiting·SShanghai Changzheng Hospital·Phase 2·NCT06603376·75 enrolled

Trial1 trial

Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.

Completed· Pfizer logo

Pfizer·Phase 3·NCT00101686·547 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for FOLFIRI ± Bevacizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FOLFIRI ± Bevacizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FOLFIRI ± Bevacizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: Pfizer

FOLFIRI ± Bevacizumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Neuroendocrine Carcinoma1 trial

Colorectal Carcinoma1 trial

Colorectal Cancer1 trial

Trial1 trial

References

Drug Info

Quick Facts

Related News